Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-Lym-1
- Development stage
- Unknown
- Lead developer
- UC Davis Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
131I-Lym-1 is a radiopharmaceutical conjugate consisting of the murine monoclonal antibody Lym-1 labeled with the radioisotope Iodine-131. Lym-1 is an IgG2a antibody that specifically targets a unique epitope of the HLA-DR antigen, which is highly up-regulated on the surface of malignant B-lymphocytes in various hematologic cancers. The drug functions as a radioimmunotherapy (RAIT) agent; once the antibody binds to the target cells, the Iodine-131 delivers cytotoxic beta radiation (and gamma radiation for imaging) to the tumor site. Primarily investigated for the treatment of chemotherapy-resistant non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it demonstrated the ability to induce durable remissions. Clinical development identified dose-limiting thrombocytopenia and the common development of human anti-mouse antibodies (HAMA) as significant safety considerations.
- Other names
- Iodine-131 Lym-1Iodine131 Lym-1Iodine 131 Lym-1131I-labeled Lym-1radioiodinated Lym-1I-131-LYM-1I131-LYM-1I 131-LYM-1
02
Targets
CD20 (B-lymphocyte antigen CD20)HLA-DRA (HLA class II histocompatibility antigen DR alpha chain)
Beyond the preview
Go deeper on 131I-Lym-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 131I-Lym-1.